25 XP   0   0   10

Hanmi Pharm Co Ltd
Buy, Hold or Sell?

Let's analyse Hanmi Pharm Co Ltd together

PenkeI guess you are interested in Hanmi Pharm Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Hanmi Pharm Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Hanmi Pharm Co Ltd

I send you an email if I find something interesting about Hanmi Pharm Co Ltd.

Quick analysis of Hanmi Pharm Co Ltd (30 sec.)










What can you expect buying and holding a share of Hanmi Pharm Co Ltd? (30 sec.)

How much money do you get?

How much money do you get?
₩0.03
When do you have the money?
1 year
How often do you get paid?
65.0%

What is your share worth?

Current worth
₩86,695.42
Expected worth in 1 year
₩93,864.68
How sure are you?
77.5%

+ What do you gain per year?

Total Gains per Share
₩7,214.80
Return On Investment
2.3%

For what price can you sell your share?

Current Price per Share
₩308,500.00
Expected price per share
₩262,255 - ₩320,000
How sure are you?
50%

1. Valuation of Hanmi Pharm Co Ltd (5 min.)




Live pricePrice per Share (EOD)

₩308,500.00

Intrinsic Value Per Share

₩-106,274.76 - ₩108,488.15

Total Value Per Share

₩-19,579.34 - ₩195,183.57

2. Growth of Hanmi Pharm Co Ltd (5 min.)




Is Hanmi Pharm Co Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$770.1m$690.8m$66.9m8.8%

How much money is Hanmi Pharm Co Ltd making?

Current yearPrevious yearGrowGrow %
Making money$25.5m$14.4m$11.1m43.4%
Net Profit Margin9.8%6.2%--

How much money comes from the company's main activities?

3. Financial Health of Hanmi Pharm Co Ltd (5 min.)




What can you expect buying and holding a share of Hanmi Pharm Co Ltd? (5 min.)

Welcome investor! Hanmi Pharm Co Ltd's management wants to use your money to grow the business. In return you get a share of Hanmi Pharm Co Ltd.

What can you expect buying and holding a share of Hanmi Pharm Co Ltd?

First you should know what it really means to hold a share of Hanmi Pharm Co Ltd. And how you can make/lose money.

Speculation

The Price per Share of Hanmi Pharm Co Ltd is ₩308,500. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Hanmi Pharm Co Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Hanmi Pharm Co Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩86,695.42. Based on the TTM, the Book Value Change Per Share is ₩1,792.32 per quarter. Based on the YOY, the Book Value Change Per Share is ₩1,595.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩11.38 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Hanmi Pharm Co Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps1.900.0%2.020.0%1.140.0%0.990.0%0.930.0%
Usd Book Value Change Per Share-0.390.0%1.250.0%1.120.0%0.860.0%0.880.0%
Usd Dividend Per Share0.010.0%0.010.0%0.510.0%0.230.0%0.240.0%
Usd Total Gains Per Share-0.380.0%1.260.0%1.620.0%1.080.0%1.110.0%
Usd Price Per Share246.75-212.80-194.07-213.66-247.22-
Price to Earnings Ratio32.52-34.67-43.69-60.68-78.05-
Price-to-Total Gains Ratio-650.97--201.74-256.36-91.32-187.40-
Price to Book Ratio4.07-3.56-3.57-4.28-5.86-
Price-to-Total Gains Ratio-650.97--201.74-256.36-91.32-187.40-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share215.95
Number of shares4
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.23
Usd Book Value Change Per Share1.250.86
Usd Total Gains Per Share1.261.08
Gains per Quarter (4 shares)5.054.34
Gains per Year (4 shares)20.2017.36
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1020104147
20403072724
306050114141
418070155558
5110090186975
61120110228292
711411302596109
8116115029110126
9118117033123143
10120119036137160

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%19.01.00.095.0%36.03.01.090.0%43.03.02.089.6%
Book Value Change Per Share2.02.00.050.0%9.03.00.075.0%15.05.00.075.0%29.011.00.072.5%36.012.00.075.0%
Dividend per Share2.00.02.050.0%10.00.02.083.3%16.00.04.080.0%26.00.014.065.0%26.00.022.054.2%
Total Gains per Share2.02.00.050.0%10.02.00.083.3%16.04.00.080.0%31.09.00.077.5%38.010.00.079.2%

Fundamentals of Hanmi Pharm Co Ltd

About Hanmi Pharm Co Ltd

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company was founded in 1973 and is based in Hwaseong-si, South Korea.

Fundamental data was last updated by Penke on 2024-04-15 20:15:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of Hanmi Pharm Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Hanmi Pharm Co Ltd earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Hanmi Pharm Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 8.1% means that ₩0.08 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Hanmi Pharm Co Ltd:

  • The MRQ is 8.1%. The company is making a profit. +1
  • The TTM is 9.8%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ8.1%TTM9.8%-1.6%
TTM9.8%YOY6.2%+3.6%
TTM9.8%5Y5.5%+4.3%
5Y5.5%10Y5.1%+0.3%
1.1.2. Return on Assets

Shows how efficient Hanmi Pharm Co Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Hanmi Pharm Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.8% Return on Assets means that Hanmi Pharm Co Ltd generated ₩0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Hanmi Pharm Co Ltd:

  • The MRQ is 1.8%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.9%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.8%TTM1.9%-0.1%
TTM1.9%YOY1.1%+0.8%
TTM1.9%5Y0.9%+1.0%
5Y0.9%10Y1.0%-0.1%
1.1.3. Return on Equity

Shows how efficient Hanmi Pharm Co Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Hanmi Pharm Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 3.6% Return on Equity means Hanmi Pharm Co Ltd generated ₩0.04 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Hanmi Pharm Co Ltd:

  • The MRQ is 3.6%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.9%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.6%TTM3.9%-0.3%
TTM3.9%YOY2.4%+1.4%
TTM3.9%5Y2.1%+1.7%
5Y2.1%10Y2.3%-0.2%

1.2. Operating Efficiency of Hanmi Pharm Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Hanmi Pharm Co Ltd is operating .

  • Measures how much profit Hanmi Pharm Co Ltd makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Hanmi Pharm Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Hanmi Pharm Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY11.5%-11.5%
TTM-5Y8.3%-8.3%
5Y8.3%10Y5.7%+2.6%
1.2.2. Operating Ratio

Measures how efficient Hanmi Pharm Co Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.25 means that the operating costs are ₩1.25 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Hanmi Pharm Co Ltd:

  • The MRQ is 1.248. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.296. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.248TTM1.296-0.048
TTM1.296YOY1.136+0.160
TTM1.2965Y1.270+0.026
5Y1.27010Y1.049+0.221

1.3. Liquidity of Hanmi Pharm Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Hanmi Pharm Co Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.04 means the company has ₩1.04 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Hanmi Pharm Co Ltd:

  • The MRQ is 1.037. The company is just able to pay all its short-term debts.
  • The TTM is 1.061. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.037TTM1.061-0.024
TTM1.061YOY1.061+0.000
TTM1.0615Y1.161-0.101
5Y1.16110Y0.869+0.292
1.3.2. Quick Ratio

Measures if Hanmi Pharm Co Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Hanmi Pharm Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.52 means the company can pay off ₩0.52 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Hanmi Pharm Co Ltd:

  • The MRQ is 0.523. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.389. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.523TTM0.389+0.133
TTM0.389YOY0.401-0.012
TTM0.3895Y0.399-0.010
5Y0.39910Y0.644-0.246

1.4. Solvency of Hanmi Pharm Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Hanmi Pharm Co Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Hanmi Pharm Co Ltd to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.42 means that Hanmi Pharm Co Ltd assets are financed with 42.1% credit (debt) and the remaining percentage (100% - 42.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Hanmi Pharm Co Ltd:

  • The MRQ is 0.421. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.435. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.421TTM0.435-0.015
TTM0.435YOY0.495-0.060
TTM0.4355Y0.523-0.088
5Y0.52310Y0.509+0.014
1.4.2. Debt to Equity Ratio

Measures if Hanmi Pharm Co Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Hanmi Pharm Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 83.6% means that company has ₩0.84 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Hanmi Pharm Co Ltd:

  • The MRQ is 0.836. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.892. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.836TTM0.892-0.056
TTM0.892YOY1.141-0.250
TTM0.8925Y1.286-0.394
5Y1.28610Y1.197+0.089

2. Market Valuation of Hanmi Pharm Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Hanmi Pharm Co Ltd generates.

  • Above 15 is considered overpriced but always compare Hanmi Pharm Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 32.52 means the investor is paying ₩32.52 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Hanmi Pharm Co Ltd:

  • The EOD is 28.457. Based on the earnings, the company is overpriced. -1
  • The MRQ is 32.515. Based on the earnings, the company is overpriced. -1
  • The TTM is 34.673. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD28.457MRQ32.515-4.059
MRQ32.515TTM34.673-2.158
TTM34.673YOY43.688-9.016
TTM34.6735Y60.680-26.008
5Y60.68010Y78.051-17.370
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Hanmi Pharm Co Ltd:

  • The EOD is 34.535. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 39.460. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 25.943. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD34.535MRQ39.460-4.926
MRQ39.460TTM25.943+13.518
TTM25.943YOY8.958+16.985
TTM25.9435Y108.986-83.044
5Y108.98610Y48.857+60.129
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Hanmi Pharm Co Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 4.07 means the investor is paying ₩4.07 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Hanmi Pharm Co Ltd:

  • The EOD is 3.558. Based on the equity, the company is fair priced.
  • The MRQ is 4.066. Based on the equity, the company is fair priced.
  • The TTM is 3.562. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.558MRQ4.066-0.508
MRQ4.066TTM3.562+0.504
TTM3.562YOY3.572-0.011
TTM3.5625Y4.279-0.718
5Y4.27910Y5.855-1.576
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Hanmi Pharm Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---551.5581792.316-131%1595.037-135%1225.136-145%1255.453-144%
Book Value Per Share--86695.41985306.587+2%77770.283+11%72553.424+19%62863.146+38%
Current Ratio--1.0371.061-2%1.061-2%1.161-11%0.869+19%
Debt To Asset Ratio--0.4210.435-3%0.495-15%0.523-20%0.509-17%
Debt To Equity Ratio--0.8360.892-6%1.141-27%1.286-35%1.197-30%
Dividend Per Share--10.06111.385-12%722.718-99%324.616-97%335.836-97%
Eps--2710.2752880.715-6%1630.979+66%1418.844+91%1332.101+103%
Free Cash Flow Per Share--2233.2713404.140-34%2219.689+1%1500.112+49%1316.368+70%
Free Cash Flow To Equity Per Share--2233.2713404.140-34%1493.422+50%1433.962+56%2479.505-10%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.975+3%
Intrinsic Value_10Y_max--108488.152--------
Intrinsic Value_10Y_min---106274.761--------
Intrinsic Value_1Y_max--11765.753--------
Intrinsic Value_1Y_min--2578.666--------
Intrinsic Value_3Y_max--34669.638--------
Intrinsic Value_3Y_min---3663.461--------
Intrinsic Value_5Y_max--56751.921--------
Intrinsic Value_5Y_min---22364.042--------
Market Cap3915019250000.000-14%4473411120000.0003857920015165.829+16%3518440020291.975+27%3873458103461.800+15%4676639194509.604-4%
Net Profit Margin--0.0810.098-17%0.062+31%0.055+49%0.051+59%
Operating Margin----0%0.115-100%0.083-100%0.057-100%
Operating Ratio--1.2481.296-4%1.136+10%1.270-2%1.049+19%
Pb Ratio3.558-14%4.0663.562+14%3.572+14%4.279-5%5.855-31%
Pe Ratio28.457-14%32.51534.673-6%43.688-26%60.680-46%78.051-58%
Price Per Share308500.000-14%352500.000303999.961+16%277249.913+27%305224.885+15%353169.7890%
Price To Free Cash Flow Ratio34.535-14%39.46025.943+52%8.958+341%108.986-64%48.857-19%
Price To Total Gains Ratio-569.717+12%-650.973-201.743-69%256.359-354%91.319-813%187.403-447%
Quick Ratio--0.5230.389+34%0.401+30%0.399+31%0.644-19%
Return On Assets--0.0180.019-4%0.011+71%0.009+94%0.010+80%
Return On Equity--0.0360.039-7%0.024+48%0.021+69%0.023+56%
Total Gains Per Share---541.4971803.701-130%2317.755-123%1549.752-135%1591.290-134%
Usd Book Value--770147450.905757809941.583+2%690860644.772+11%644517793.185+19%570412029.899+35%
Usd Book Value Change Per Share---0.3861.255-131%1.117-135%0.858-145%0.879-144%
Usd Book Value Per Share--60.68759.715+2%54.439+11%50.787+19%44.004+38%
Usd Dividend Per Share--0.0070.008-12%0.506-99%0.227-97%0.235-97%
Usd Eps--1.8972.017-6%1.142+66%0.993+91%0.932+103%
Usd Free Cash Flow--19838971.33430240232.838-34%19718276.314+1%13326030.296+49%8701350.385+128%
Usd Free Cash Flow Per Share--1.5632.383-34%1.554+1%1.050+49%0.921+70%
Usd Free Cash Flow To Equity Per Share--1.5632.383-34%1.045+50%1.004+56%1.736-10%
Usd Market Cap2740513475.000-14%3131387784.0002700544010.616+16%2462908014.204+27%2711420672.423+15%3273647436.157-4%
Usd Price Per Share215.950-14%246.750212.800+16%194.075+27%213.657+15%247.2190%
Usd Profit--24076371.73225590452.605-6%14488553.825+66%12604101.580+91%11995224.357+101%
Usd Revenue--295645521.717260905306.151+13%233020655.005+27%217529308.684+36%194411188.884+52%
Usd Total Gains Per Share---0.3791.263-130%1.622-123%1.085-135%1.114-134%
 EOD+5 -3MRQTTM+12 -22YOY+22 -135Y+25 -1010Y+21 -15

3.2. Fundamental Score

Let's check the fundamental score of Hanmi Pharm Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1528.457
Price to Book Ratio (EOD)Between0-13.558
Net Profit Margin (MRQ)Greater than00.081
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.523
Current Ratio (MRQ)Greater than11.037
Debt to Asset Ratio (MRQ)Less than10.421
Debt to Equity Ratio (MRQ)Less than10.836
Return on Equity (MRQ)Greater than0.150.036
Return on Assets (MRQ)Greater than0.050.018
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Hanmi Pharm Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.634
Ma 20Greater thanMa 50320,350.000
Ma 50Greater thanMa 100327,570.000
Ma 100Greater thanMa 200327,150.282
OpenGreater thanClose312,000.000
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets1,898,668,376
Total Liabilities798,457,732
Total Stockholder Equity955,442,390
 As reported
Total Liabilities 798,457,732
Total Stockholder Equity+ 955,442,390
Total Assets = 1,898,668,376

Assets

Total Assets1,898,668,376
Total Current Assets730,623,668
Long-term Assets1,168,044,708
Total Current Assets
Cash And Cash Equivalents 54,980,324
Short-term Investments 200,202,440
Net Receivables 168,139,407
Inventory 288,813,765
Other Current Assets 99,810
Total Current Assets  (as reported)730,623,668
Total Current Assets  (calculated)712,235,747
+/- 18,387,921
Long-term Assets
Property Plant Equipment 860,241,957
Intangible Assets 81,045,156
Long-term Assets Other 0
Long-term Assets  (as reported)1,168,044,708
Long-term Assets  (calculated)941,287,113
+/- 226,757,596

Liabilities & Shareholders' Equity

Total Current Liabilities704,762,991
Long-term Liabilities93,694,740
Total Stockholder Equity955,442,390
Total Current Liabilities
Short Long Term Debt 481,450,760
Accounts payable 45,180,264
Other Current Liabilities 2
Total Current Liabilities  (as reported)704,762,991
Total Current Liabilities  (calculated)526,631,026
+/- 178,131,966
Long-term Liabilities
Long term Debt 82,028,400
Capital Lease Obligations Min Short Term Debt9,388,106
Long-term Liabilities Other -1
Long-term Liabilities  (as reported)93,694,740
Long-term Liabilities  (calculated)91,416,505
+/- 2,278,235
Total Stockholder Equity
Retained Earnings 581,978,730
Total Stockholder Equity (as reported)955,442,390
Total Stockholder Equity (calculated)581,978,730
+/- 373,463,660
Other
Capital Stock31,405,395
Common Stock Shares Outstanding 12,691
Net Debt 508,498,836
Net Invested Capital 1,518,921,550
Net Working Capital 25,860,676
Property Plant and Equipment Gross 1,495,148,297



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-31
> Total Assets 
827,010,293
845,560,913
844,579,458
835,591,466
862,416,132
869,293,327
871,366,238
880,869,229
987,791,075
1,001,870,609
1,017,988,011
1,033,334,526
1,054,206,896
1,137,277,569
1,179,270,807
1,722,592,753
1,581,841,087
1,537,625,562
1,513,150,762
1,596,970,589
1,478,084,719
1,539,183,722
1,641,949,739
1,660,934,086
1,685,116,601
1,748,843,824
1,742,310,631
1,691,209,669
1,857,036,430
1,892,720,147
1,932,132,948
1,913,706,258
1,974,114,579
1,973,036,077
1,947,320,022
1,882,026,593
1,939,532,427
1,925,945,058
1,948,106,375
1,936,728,687
1,975,385,438
1,940,324,732
1,984,055,391
1,924,585,731
1,996,002,570
1,865,962,595
1,912,996,686
1,898,668,376
1,898,668,3761,912,996,6861,865,962,5951,996,002,5701,924,585,7311,984,055,3911,940,324,7321,975,385,4381,936,728,6871,948,106,3751,925,945,0581,939,532,4271,882,026,5931,947,320,0221,973,036,0771,974,114,5791,913,706,2581,932,132,9481,892,720,1471,857,036,4301,691,209,6691,742,310,6311,748,843,8241,685,116,6011,660,934,0861,641,949,7391,539,183,7221,478,084,7191,596,970,5891,513,150,7621,537,625,5621,581,841,0871,722,592,7531,179,270,8071,137,277,5691,054,206,8961,033,334,5261,017,988,0111,001,870,609987,791,075880,869,229871,366,238869,293,327862,416,132835,591,466844,579,458845,560,913827,010,293
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
840,741,793
672,942,533
660,708,661
680,333,183
658,090,966
646,934,682
688,705,882
660,106,238
564,093,421
657,048,802
673,224,892
687,567,949
662,204,137
730,354,553
703,059,642
674,986,814
614,373,231
681,034,026
679,075,327
705,595,765
703,509,260
726,558,431
701,998,182
744,630,788
694,158,251
784,137,979
667,482,154
730,527,531
730,623,668
730,623,668730,527,531667,482,154784,137,979694,158,251744,630,788701,998,182726,558,431703,509,260705,595,765679,075,327681,034,026614,373,231674,986,814703,059,642730,354,553662,204,137687,567,949673,224,892657,048,802564,093,421660,106,238688,705,882646,934,682658,090,966680,333,183660,708,661672,942,533840,741,7930000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
130,372,331
110,985,027
83,406,406
83,558,223
47,266,027
53,762,741
77,781,786
81,809,604
67,338,195
86,321,594
84,357,760
92,180,858
106,113,064
134,123,802
112,565,414
118,921,924
146,157,369
160,997,769
172,655,210
205,773,177
209,224,626
191,865,546
154,070,194
177,931,504
147,328,655
188,942,211
149,570,246
188,169,200
54,980,324
54,980,324188,169,200149,570,246188,942,211147,328,655177,931,504154,070,194191,865,546209,224,626205,773,177172,655,210160,997,769146,157,369118,921,924112,565,414134,123,802106,113,06492,180,85884,357,76086,321,59467,338,19581,809,60477,781,78653,762,74147,266,02783,558,22383,406,406110,985,027130,372,3310000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
197,353,741
66,494,462
80,324,044
72,999,779
71,665,131
68,260,070
27,550,127
26,545,376
31,357,894
46,418,009
27,589,110
9,845,790
1,978,954
19,524,518
47,701,229
26,941,797
1,874,264
23,747,784
12,215,929
2,587,247
2,509,726
93,510,179
101,264,480
82,342,072
89,407,763
129,263,749
73,409,496
71,184,491
200,202,440
200,202,44071,184,49173,409,496129,263,74989,407,76382,342,072101,264,48093,510,1792,509,7262,587,24712,215,92923,747,7841,874,26426,941,79747,701,22919,524,5181,978,9549,845,79027,589,11046,418,00931,357,89426,545,37627,550,12768,260,07071,665,13172,999,77980,324,04466,494,462197,353,7410000000000000000000
       Net Receivables 
193,600,859
217,786,494
215,579,475
203,168,085
203,960,747
198,202,501
201,495,242
220,954,482
239,792,907
264,159,941
258,953,899
289,897,516
291,830,298
266,026,130
337,141,598
784,556,920
271,769,014
254,424,254
250,690,011
271,539,423
252,747,873
238,281,837
255,071,634
249,646,109
244,151,390
242,248,757
236,204,250
182,515,967
209,090,901
224,358,970
228,574,350
190,091,132
223,854,854
195,154,616
208,731,135
149,220,200
189,430,260
193,779,092
205,537,598
222,608,646
168,506,533
168,182,399
201,672,316
180,059,898
155,822,401
122,069,232
153,305,608
168,139,407
168,139,407153,305,608122,069,232155,822,401180,059,898201,672,316168,182,399168,506,533222,608,646205,537,598193,779,092189,430,260149,220,200208,731,135195,154,616223,854,854190,091,132228,574,350224,358,970209,090,901182,515,967236,204,250242,248,757244,151,390249,646,109255,071,634238,281,837252,747,873271,539,423250,690,011254,424,254271,769,014784,556,920337,141,598266,026,130291,830,298289,897,516258,953,899264,159,941239,792,907220,954,482201,495,242198,202,501203,960,747203,168,085215,579,475217,786,494193,600,859
       Other Current Assets 
17,867,948
14,857,659
9,800,564
10,023,862
14,224,301
16,093,366
16,663,385
15,321,443
23,594,898
25,008,339
29,102,849
16,861,180
11,798,389
11,468,622
18,373,432
19,894,257
73,343,026
99,230,119
92,173,128
48,617,762
111,057,307
122,920,036
113,606,399
35,935,437
103,077,838
38,785,243
37,030,801
6,666,004
34,015,064
37,140,785
33,916,973
9,073,967
35,356,209
10,972,760
10,561,456
7,844,129
4,205,561
5,888,850
7,797,234
8,466,380
22,071,851
21,643,667
23,674,754
6,581,358
31,926
97,919
56,045
99,810
99,81056,04597,91931,9266,581,35823,674,75421,643,66722,071,8518,466,3807,797,2345,888,8504,205,5617,844,12910,561,45610,972,76035,356,2099,073,96733,916,97337,140,78534,015,0646,666,00437,030,80138,785,243103,077,83835,935,437113,606,399122,920,036111,057,30748,617,76292,173,12899,230,11973,343,02619,894,25718,373,43211,468,62211,798,38916,861,18029,102,84925,008,33923,594,89815,321,44316,663,38516,093,36614,224,30110,023,8629,800,56414,857,65917,867,948
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,199,987,629
1,219,495,255
1,244,564,999
1,251,502,120
1,243,760,026
1,269,976,436
1,272,333,208
1,267,653,363
1,258,498,402
1,246,869,731
1,242,510,610
1,232,767,093
1,248,827,007
1,238,326,550
1,239,424,603
1,230,427,480
1,211,864,591
1,198,480,441
1,182,469,155
1,168,044,708
1,168,044,7081,182,469,1551,198,480,4411,211,864,5911,230,427,4801,239,424,6031,238,326,5501,248,827,0071,232,767,0931,242,510,6101,246,869,7311,258,498,4021,267,653,3631,272,333,2081,269,976,4361,243,760,0261,251,502,1201,244,564,9991,219,495,2551,199,987,6290000000000000000000000000000
       Property Plant Equipment 
258,738,267
253,337,694
248,480,257
242,093,099
256,313,260
256,572,442
258,082,970
259,377,148
261,539,980
269,506,403
286,819,999
327,872,025
344,149,875
365,037,858
386,911,378
415,734,361
439,274,433
490,748,809
541,893,409
598,936,037
642,016,445
703,903,171
751,511,212
790,051,542
823,056,897
842,469,422
862,215,059
900,316,958
928,628,198
957,326,566
983,490,077
999,511,907
1,004,177,381
1,002,201,594
1,004,195,054
1,000,040,363
989,895,056
974,548,154
964,495,175
957,218,235
947,916,456
937,111,313
944,214,605
917,981,544
903,570,416
886,855,259
871,876,984
860,241,957
860,241,957871,876,984886,855,259903,570,416917,981,544944,214,605937,111,313947,916,456957,218,235964,495,175974,548,154989,895,0561,000,040,3631,004,195,0541,002,201,5941,004,177,381999,511,907983,490,077957,326,566928,628,198900,316,958862,215,059842,469,422823,056,897790,051,542751,511,212703,903,171642,016,445598,936,037541,893,409490,748,809439,274,433415,734,361386,911,378365,037,858344,149,875327,872,025286,819,999269,506,403261,539,980259,377,148258,082,970256,572,442256,313,260242,093,099248,480,257253,337,694258,738,267
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26,189,847
26,681,089
27,076,099
56,875,759
54,396,696
55,438,119
61,266,403
72,421,286
53,282,763
84,243,282
90,232,414
75,776,251
67,005,712
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000067,005,71275,776,25190,232,41484,243,28253,282,76372,421,28661,266,40355,438,11954,396,69656,875,75927,076,09926,681,08926,189,8470000000000000000000
       Intangible Assets 
19,451,956
18,560,564
17,762,512
17,163,576
16,955,094
17,105,337
16,921,041
14,727,277
15,562,487
15,556,774
15,110,857
14,873,032
14,931,503
15,371,503
16,148,990
20,419,611
22,499,541
23,292,284
24,199,330
27,797,690
27,084,480
28,813,280
29,800,762
29,352,677
30,507,603
31,145,879
36,368,660
38,131,447
63,221,748
64,606,793
67,483,250
66,243,786
64,846,199
66,175,159
67,787,526
72,886,266
73,683,035
75,748,456
77,165,031
80,169,618
79,944,774
86,152,173
85,881,622
84,586,823
86,307,858
84,285,268
84,619,941
81,045,156
81,045,15684,619,94184,285,26886,307,85884,586,82385,881,62286,152,17379,944,77480,169,61877,165,03175,748,45673,683,03572,886,26667,787,52666,175,15964,846,19966,243,78667,483,25064,606,79363,221,74838,131,44736,368,66031,145,87930,507,60329,352,67729,800,76228,813,28027,084,48027,797,69024,199,33023,292,28422,499,54120,419,61116,148,99015,371,50314,931,50314,873,03215,110,85715,556,77415,562,48714,727,27716,921,04117,105,33716,955,09417,163,57617,762,51218,560,56419,451,956
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19,217,328
10,967,410
19,523,432
-933,975
11,791,045
38,522,700
38,809,183
203,126
38,716,463
39,795,409
40,006,532
181,153
41,254,075
39,097,736
38,912,758
150,937
87,227
1
0
0
00187,227150,93738,912,75839,097,73641,254,075181,15340,006,53239,795,40938,716,463203,12638,809,18338,522,70011,791,045-933,97519,523,43210,967,41019,217,3280000000000000000000000000000
> Total Liabilities 
451,636,090
464,981,068
446,040,715
426,248,298
425,354,032
425,110,429
407,647,338
417,954,180
412,791,908
424,018,710
429,222,340
444,088,361
452,805,483
513,642,791
581,565,648
977,784,819
825,524,811
767,423,197
747,647,447
862,453,635
736,531,857
779,061,483
842,380,652
868,509,824
904,719,410
954,202,934
945,045,683
901,953,197
1,051,448,835
1,072,762,508
1,102,673,891
1,091,444,833
1,144,071,052
1,138,903,836
1,139,329,636
1,050,137,119
1,086,277,183
1,058,865,915
1,041,345,062
1,008,469,279
1,029,013,253
967,302,968
964,900,909
915,359,049
927,608,174
811,435,322
805,786,476
798,457,732
798,457,732805,786,476811,435,322927,608,174915,359,049964,900,909967,302,9681,029,013,2531,008,469,2791,041,345,0621,058,865,9151,086,277,1831,050,137,1191,139,329,6361,138,903,8361,144,071,0521,091,444,8331,102,673,8911,072,762,5081,051,448,835901,953,197945,045,683954,202,934904,719,410868,509,824842,380,652779,061,483736,531,857862,453,635747,647,447767,423,197825,524,811977,784,819581,565,648513,642,791452,805,483444,088,361429,222,340424,018,710412,791,908417,954,180407,647,338425,110,429425,354,032426,248,298446,040,715464,981,068451,636,090
   > Total Current Liabilities 
217,153,904
241,026,553
291,712,865
282,034,552
309,956,087
301,069,643
218,071,819
233,860,415
204,478,800
174,475,865
178,107,643
182,354,086
179,484,359
205,263,607
272,034,646
673,621,349
581,998,154
527,652,617
545,537,084
544,144,964
419,201,838
458,947,298
566,522,950
639,175,467
652,330,825
559,546,301
547,437,396
434,972,757
588,837,788
467,680,846
489,267,012
471,803,222
518,805,896
602,966,928
559,010,214
533,451,266
556,671,360
636,990,142
658,472,840
648,938,236
679,332,895
659,885,260
686,640,539
676,748,303
697,112,751
659,398,792
682,721,569
704,762,991
704,762,991682,721,569659,398,792697,112,751676,748,303686,640,539659,885,260679,332,895648,938,236658,472,840636,990,142556,671,360533,451,266559,010,214602,966,928518,805,896471,803,222489,267,012467,680,846588,837,788434,972,757547,437,396559,546,301652,330,825639,175,467566,522,950458,947,298419,201,838544,144,964545,537,084527,652,617581,998,154673,621,349272,034,646205,263,607179,484,359182,354,086178,107,643174,475,865204,478,800233,860,415218,071,819301,069,643309,956,087282,034,552291,712,865241,026,553217,153,904
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
332,221,397
326,155,303
373,401,933
103,739,349
108,257,037
88,274,634
78,289,362
18,300,000
13,800,000
339,400,000
300,861,686
313,873,808
296,885,995
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000296,885,995313,873,808300,861,686339,400,00013,800,00018,300,00078,289,36288,274,634108,257,037103,739,349373,401,933326,155,303332,221,3970000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
332,221,397
326,155,303
373,401,933
103,739,349
108,257,037
88,274,634
78,289,362
18,300,000
13,800,000
339,400,000
300,861,686
313,873,808
296,885,995
345,898,245
408,027,584
417,321,842
399,823,423
424,930,274
490,148,138
443,344,208
400,025,445
434,303,090
421,350,355
400,264,150
449,463,670
461,470,386
437,483,099
461,581,149
481,450,760
481,450,760461,581,149437,483,099461,470,386449,463,670400,264,150421,350,355434,303,090400,025,445443,344,208490,148,138424,930,274399,823,423417,321,842408,027,584345,898,245296,885,995313,873,808300,861,686339,400,00013,800,00018,300,00078,289,36288,274,634108,257,037103,739,349373,401,933326,155,303332,221,3970000000000000000000
       Accounts payable 
35,756,144
36,911,045
35,997,008
34,032,288
32,728,005
36,894,471
33,099,530
38,401,181
39,110,520
41,845,605
46,816,138
52,826,399
45,319,748
48,104,845
56,812,428
56,176,661
43,711,018
44,460,073
46,402,365
50,598,946
48,066,866
44,072,481
36,267,926
46,566,648
40,268,923
44,481,751
36,483,837
44,475,417
45,710,332
43,758,396
51,244,441
37,509,150
36,820,257
37,865,725
32,703,344
32,214,491
28,210,721
31,689,848
34,569,071
42,833,379
42,578,978
39,101,979
38,600,382
39,709,501
51,960,489
44,606,497
38,386,927
45,180,264
45,180,26438,386,92744,606,49751,960,48939,709,50138,600,38239,101,97942,578,97842,833,37934,569,07131,689,84828,210,72132,214,49132,703,34437,865,72536,820,25737,509,15051,244,44143,758,39645,710,33244,475,41736,483,83744,481,75140,268,92346,566,64836,267,92644,072,48148,066,86650,598,94646,402,36544,460,07343,711,01856,176,66156,812,42848,104,84545,319,74852,826,39946,816,13841,845,60539,110,52038,401,18133,099,53036,894,47132,728,00534,032,28835,997,00836,911,04535,756,144
       Other Current Liabilities 
46,051,988
57,073,039
58,593,231
52,670,846
57,076,473
54,968,296
56,478,550
67,664,411
61,139,840
65,947,215
69,233,564
82,671,456
76,843,863
77,941,139
98,044,991
514,249,317
368,834,674
343,658,352
318,896,323
322,239,986
234,950,753
260,511,025
289,007,759
314,020,962
308,381,319
232,416,368
200,205,433
144,342,888
195,273,914
0
1
102,910,748
121,282,866
145,670,032
97,218,775
88,104,300
83,672,506
97,595,141
163,851,059
139,835,432
130,140,643
178,985,037
230,687,328
133,456,320
1
1
1
2
2111133,456,320230,687,328178,985,037130,140,643139,835,432163,851,05997,595,14183,672,50688,104,30097,218,775145,670,032121,282,866102,910,74810195,273,914144,342,888200,205,433232,416,368308,381,319314,020,962289,007,759260,511,025234,950,753322,239,986318,896,323343,658,352368,834,674514,249,31798,044,99177,941,13976,843,86382,671,45669,233,56465,947,21561,139,84067,664,41156,478,55054,968,29657,076,47352,670,84658,593,23157,073,03946,051,988
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
462,611,047
605,081,662
613,406,879
619,641,611
625,265,156
535,936,909
580,319,422
516,685,853
529,605,823
421,875,773
382,872,222
359,531,042
349,680,358
307,417,708
278,260,371
238,610,746
230,495,423
152,036,530
123,064,906
93,694,740
93,694,740123,064,906152,036,530230,495,423238,610,746278,260,371307,417,708349,680,358359,531,042382,872,222421,875,773529,605,823516,685,853580,319,422535,936,909625,265,156619,641,611613,406,879605,081,662462,611,0470000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-332,221,397
-326,155,303
-373,401,933
-103,739,349
-108,257,037
-88,274,634
-78,289,362
-18,300,000
-13,800,000
-327,868,850
-289,590,377
-303,657,112
-287,097,800
10,462,121
9,891,288
9,562,246
13,401,893
13,508,931
13,097,979
13,436,287
65,622,199
66,310,656
12,889,695
3,274,899
48,215,134
11,444,342
10,813,609
9,821,393
9,388,106
9,388,1069,821,39310,813,60911,444,34248,215,1343,274,89912,889,69566,310,65665,622,19913,436,28713,097,97913,508,93113,401,8939,562,2469,891,28810,462,121-287,097,800-303,657,112-289,590,377-327,868,850-13,800,000-18,300,000-78,289,362-88,274,634-108,257,037-103,739,349-373,401,933-326,155,303-332,221,3970000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
0
0
0
0
0
0
0
-1
0
0
-1
0
0
0
0
0
1
0
-1
-10100000-100-10000000-10000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,270,029
15,142,068
17,132,592
19,494,725
16,350,909
15,116,318
16,657,457
17,682,512
22,558,139
23,912,646
26,054,305
27,499,222
23,783,089
22,423,415
23,770,812
24,884,733
25,325,429
26,263,579
26,756,780
27,840,472
31,461,369
32,821,781
39,705,361
39,908,489
36,579,639
0
0
0
0
000036,579,63939,908,48939,705,36132,821,78131,461,36927,840,47226,756,78026,263,57925,325,42924,884,73323,770,81222,423,41523,783,08927,499,22226,054,30523,912,64622,558,13917,682,51216,657,45715,116,31816,350,90919,494,72517,132,59215,142,06812,270,0290000000000000000000
> Total Stockholder Equity
331,921,536
335,887,496
351,851,949
362,423,774
386,867,925
392,096,800
411,583,292
409,385,160
519,627,589
522,782,290
530,238,689
527,462,859
535,890,955
556,154,781
527,103,719
674,945,183
684,306,564
697,655,692
694,171,118
659,461,200
663,839,311
681,182,156
717,083,044
711,710,952
697,756,876
711,128,668
714,357,862
703,228,123
712,889,955
725,486,602
732,392,292
723,795,039
727,077,595
734,017,543
707,330,290
729,987,421
744,818,655
756,339,563
787,316,041
802,913,731
817,511,767
838,415,080
874,662,406
871,865,586
919,777,364
917,174,786
961,947,714
955,442,390
955,442,390961,947,714917,174,786919,777,364871,865,586874,662,406838,415,080817,511,767802,913,731787,316,041756,339,563744,818,655729,987,421707,330,290734,017,543727,077,595723,795,039732,392,292725,486,602712,889,955703,228,123714,357,862711,128,668697,756,876711,710,952717,083,044681,182,156663,839,311659,461,200694,171,118697,655,692684,306,564674,945,183527,103,719556,154,781535,890,955527,462,859530,238,689522,782,290519,627,589409,385,160411,583,292392,096,800386,867,925362,423,774351,851,949335,887,496331,921,536
   Common Stock
19,718,190
19,718,190
19,718,190
19,718,190
20,702,790
20,702,790
20,702,790
20,702,790
24,361,305
24,361,305
24,361,305
24,361,305
25,577,273
25,577,273
25,577,273
25,577,273
26,087,778
26,087,778
26,087,778
26,087,778
27,908,630
27,908,630
27,908,630
27,908,630
28,464,228
28,464,228
28,464,228
28,464,228
29,030,460
29,030,460
29,030,460
29,030,460
29,607,573
29,607,573
29,607,573
29,607,573
30,195,705
30,195,705
30,195,705
30,195,705
30,794,928
30,794,928
30,794,928
30,794,928
0
0
0
0
000030,794,92830,794,92830,794,92830,794,92830,195,70530,195,70530,195,70530,195,70529,607,57329,607,57329,607,57329,607,57329,030,46029,030,46029,030,46029,030,46028,464,22828,464,22828,464,22828,464,22827,908,63027,908,63027,908,63027,908,63026,087,77826,087,77826,087,77826,087,77825,577,27325,577,27325,577,27325,577,27324,361,30524,361,30524,361,30524,361,30520,702,79020,702,79020,702,79020,702,79019,718,19019,718,19019,718,19019,718,190
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000000000000000000000
   Capital Surplus 000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000-21,318,412-21,318,412-21,318,412-15,730,389-15,730,389-15,730,389-15,730,389-9,280,280-9,280,279-9,280,279-9,280,280-2,153,135-2,153,135-2,153,135-2,153,135-1,744,570-1,744,570-1,744,570-1,744,569-1,228,042-1,228,042-1,228,041-1,228,041-880,336-880,336-880,336-880,336
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-3,522,754
-11,621,394
-6,748,052
8,514,700
-1,218,860
-2,981,024
-1,659,811
-9,951,525
-6,624,988
40,136
-5,703,594
-5,274,349
-18,161,101
-13,564,772
-14,107,045
-9,950,965
-19,231,075
-12,688,714
-8,279,816
-704,873
-4,230,377
24,370,037
26,850,960
37,723,996
13,173,948
0
0
0
0
000013,173,94837,723,99626,850,96024,370,037-4,230,377-704,873-8,279,816-12,688,714-19,231,075-9,950,965-14,107,045-13,564,772-18,161,101-5,274,349-5,703,59440,136-6,624,988-9,951,525-1,659,811-2,981,024-1,218,8608,514,700-6,748,052-11,621,394-3,522,7540000000000000000000



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,490,887,464
Cost of Revenue-661,638,121
Gross Profit829,249,343829,249,343
 
Operating Income (+$)
Gross Profit829,249,343
Operating Expense-1,266,002,549
Operating Income224,884,915-436,753,205
 
Operating Expense (+$)
Research Development181,769,141
Selling General Administrative248,243,028
Selling And Marketing Expenses0
Operating Expense1,266,002,549430,012,169
 
Net Interest Income (+$)
Interest Income4,617,726
Interest Expense-28,508,409
Other Finance Cost-978,067
Net Interest Income-24,868,750
 
Pretax Income (+$)
Operating Income224,884,915
Net Interest Income-24,868,750
Other Non-Operating Income Expenses0
Income Before Tax (EBT)193,966,774224,884,915
EBIT - interestExpense = -28,508,409
146,231,158
174,739,567
Interest Expense28,508,409
Earnings Before Interest and Taxes (EBIT)0222,475,183
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax193,966,774
Tax Provision-28,600,596
Net Income From Continuing Ops165,366,178165,366,178
Net Income146,231,158
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net024,868,750
 

Technical Analysis of Hanmi Pharm Co Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Hanmi Pharm Co Ltd. The general trend of Hanmi Pharm Co Ltd is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Hanmi Pharm Co Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Hanmi Pharm Co Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 315,000 < 318,000 < 320,000.

The bearish price targets are: 282,353 > 264,706 > 262,255.

Tweet this
Hanmi Pharm Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Hanmi Pharm Co Ltd. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Hanmi Pharm Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Hanmi Pharm Co Ltd. The current macd is -6,735.95078305.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Hanmi Pharm Co Ltd price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Hanmi Pharm Co Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Hanmi Pharm Co Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Hanmi Pharm Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartHanmi Pharm Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Hanmi Pharm Co Ltd. The current adx is 24.71.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Hanmi Pharm Co Ltd shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Hanmi Pharm Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Hanmi Pharm Co Ltd. The current sar is 316,000.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Hanmi Pharm Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Hanmi Pharm Co Ltd. The current rsi is 43.63. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Hanmi Pharm Co Ltd Daily Relative Strength Index (RSI) ChartHanmi Pharm Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Hanmi Pharm Co Ltd. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Hanmi Pharm Co Ltd price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Hanmi Pharm Co Ltd Daily Stochastic Oscillator ChartHanmi Pharm Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Hanmi Pharm Co Ltd. The current cci is -61.10257723.

Hanmi Pharm Co Ltd Daily Commodity Channel Index (CCI) ChartHanmi Pharm Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Hanmi Pharm Co Ltd. The current cmo is -11.32971952.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Hanmi Pharm Co Ltd Daily Chande Momentum Oscillator (CMO) ChartHanmi Pharm Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Hanmi Pharm Co Ltd. The current willr is -67.53246753.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Hanmi Pharm Co Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Hanmi Pharm Co Ltd Daily Williams %R ChartHanmi Pharm Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Hanmi Pharm Co Ltd.

Hanmi Pharm Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Hanmi Pharm Co Ltd. The current atr is 10,860.

Hanmi Pharm Co Ltd Daily Average True Range (ATR) ChartHanmi Pharm Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Hanmi Pharm Co Ltd. The current obv is 1,343,482.

Hanmi Pharm Co Ltd Daily On-Balance Volume (OBV) ChartHanmi Pharm Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Hanmi Pharm Co Ltd. The current mfi is 23.41.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Hanmi Pharm Co Ltd Daily Money Flow Index (MFI) ChartHanmi Pharm Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Hanmi Pharm Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-04MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Hanmi Pharm Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Hanmi Pharm Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.634
Ma 20Greater thanMa 50320,350.000
Ma 50Greater thanMa 100327,570.000
Ma 100Greater thanMa 200327,150.282
OpenGreater thanClose312,000.000
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Hanmi Pharm Co Ltd with someone you think should read this too:
  • Are you bullish or bearish on Hanmi Pharm Co Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Hanmi Pharm Co Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Hanmi Pharm Co Ltd

I send you an email if I find something interesting about Hanmi Pharm Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Hanmi Pharm Co Ltd.

Receive notifications about Hanmi Pharm Co Ltd in your mailbox!